早期非小细胞肺癌（NSCLC）的5年生存率仍不容乐观。我们的目的是使用临床病理学 (CP) 和血清 8-miRNA 组构建预后工具来预测早期 NSCLC 的总生存 (OS) 风险。2008 年 4 月至 9 月期间总共治疗了 799 名早期 NSCLC 患者2019 年，均纳入本研究。对 280 名患者的血清样本进行了 miRNA 分析。该研究的主要终点是 OS。用于预后的 CP 组是使用多变量和向前逐步选择分析开发的。血清 8-miRNA 组是使用对预后具有重要意义的 miRNA 开发的，使用实时定量 PCR (qPCR) 进行筛选，然后进行差异分析、单变量分析和 Cox 回归分析。使用 CP 组和血清 8-miRNA 组开发组合模型。使用受试者工作特征 (ROC) 曲线的曲线下面积 (AUC) 值和 Kaplan-Meier 生存分析来评估面板和组合模型的预测性能。预后面板和组合模型（包括 CP 面板和血清 8） -miRNA panel）用于将患者分为高风险组和低风险组。两组的OS率有显着差异（P<0.05）。两个面板的 AUC 高于两个指南，并且组合模型的 AUC 最高。联合模型的AUC（AUC=0.788；95%CI 0.706-0.871）优于国家综合癌症网络（NCCN）指南（AUC=0.601；95%CI 0.505-0.697）和中国临床肿瘤学会的AUC (CSCO) 指南（AUC=0.614；95%CI 0.520-0.708）。基于 CP 组和血清 8-miRNA 组的组合模型可以更好地对早期 NSCLC 患者进行预后风险分层，以预测 OS 风险。版权所有 © 2024 Elsevier B.V. 保留所有权利。

The 5-year survival rate of early-stage non-small cell lung cancer (NSCLC) is still not optimistic. We aimed to construct prognostic tools using clinicopathological (CP) and serum 8-miRNA panel to predict the risk of overall survival (OS) in early-stage NSCLC.A total of 799 patients with early-stage NSCLC, treated between April 2008 and September 2019, were included in this study. A sub-group of patients with serum samples, 280, were analyzed for miRNA profiling. The primary endpoint of the study was OS. The CP panel for prognosis was developed using multivariate and forward stepwise selection analyses. The serum 8-miRNA panel was developed using the miRNAs that were significant for prognosis, screened using real-time quantitative PCR (qPCR) followed by differential, univariate and Cox regression analyses. The combined model was developed using CP panel and serum 8-miRNA panel. The predictive performance of the panels and the combined model was evaluated using the area under curve (AUC) values of receiver operating characteristics (ROC) curves and Kaplan-Meier survival analysis.The prognostic panels and the combined model (comprising CP panel and serum 8-miRNA panel) was used to classify the patients into high-risk and low-risk groups. The OS rates of these two groups were significantly different (P<0.05). The two panels had higher AUC than the two guidelines, and the combined model had the highest AUC. The AUC of the combined model (AUC=0.788; 95 %CI 0.706-0.871) was better than that of the National Comprehensive Cancer Network (NCCN) guideline (AUC=0.601; 95 %CI 0.505-0.697) and Chinese Society of Clinical Oncology (CSCO) guideline (AUC=0.614; 95 %CI 0.520-0.708).The combined model based on CP panel and serum 8-miRNA panel allows better prognostic risk stratification of patients with early-stage NSCLC to predict risk of OS.Copyright © 2024 Elsevier B.V. All rights reserved.